{"product_id":"natera-swot-analysis","title":"Natera SWOT Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGo Beyond the Preview—Access the Full Strategic Report\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eNatera's market position is undeniably strong, leveraging innovative diagnostic technologies and a growing presence in key healthcare sectors. Their robust R\u0026amp;D pipeline and strategic partnerships form a significant part of their strength, positioning them for continued expansion.\u003c\/p\u003e\n\u003cp\u003eHowever, understanding the full scope of their opportunities and the potential threats they face requires a deeper dive. Factors like regulatory shifts and competitive pressures can significantly impact their trajectory.\u003c\/p\u003e\n\u003cp\u003eWant the full story behind Natera's strengths, risks, and growth drivers? Purchase the complete SWOT analysis to gain access to a professionally written, fully editable report designed to support planning, pitches, and research.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etrengths\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePioneering Technology in Cell-Free DNA Testing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNatera's core strength lies in its advanced, proprietary cell-free DNA (cfDNA) technology, combining novel molecular biology with sophisticated bioinformatics and AI. This platform enables highly accurate genetic analysis from a simple blood draw, underpinning key products like the Panorama NIPT and the Signatera MRD test. With approximately 220 issued U.S. and foreign patents, this robust technological foundation provides a significant competitive advantage in the diagnostics market. This proprietary edge is crucial for Natera’s continued growth and market leadership through 2024 and 2025.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrong Revenue Growth and Improving Financials\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNatera has demonstrated robust financial performance, with total revenues surging to $1.7 billion in 2024, marking a significant 56.7% increase from 2023. This impressive growth is largely attributed to a substantial rise in test volumes, particularly in oncology, which saw a 54.9% increase during 2024. The company also improved its financial health, achieving gross margins of 60.3% in 2024. Furthermore, Natera reached a pivotal milestone by generating positive cash flow in the fourth quarter of 2024, indicating strong progress toward sustained profitability.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDiverse and Growing Product Portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eNatera demonstrates a robust and expanding product portfolio, successfully diversifying across women's health, oncology, and organ health. While the Panorama non-invasive prenatal test remains a market leader, the oncology division, particularly with the Signatera molecular residual disease (MRD) test, shows significant growth, with Q1 2024 oncology revenue increasing 61% year-over-year to $107.5 million. The company continues to innovate, with a pipeline that includes a novel tissue-free MRD assay for colorectal cancer anticipated by mid-2025, further strengthening its market position.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEstablished Market Position and Strong Brand Recognition\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eNatera has cultivated a robust market presence and strong brand recognition among healthcare providers globally, with its diagnostic tests available in over 80 countries. The company's established relationships with thousands of hospitals and clinics, numbering over 10,000 as of early 2025, consistently drive the adoption of its advanced genetic testing solutions. This market leadership is particularly evident in the non-invasive prenatal testing (NIPT) sector, where its flagship Panorama test commands a significant market share, estimated at over 50% in the US NIPT market for 2024. This widespread adoption underscores Natera's dominant position.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cstrong\u003eGlobal reach in over 80 countries by 2025.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eRelationships with over 10,000 hospitals and clinics.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003ePanorama NIPT holds over 50% US market share in 2024.\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRobust Clinical Validation and Data Leadership\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eNatera demonstrates robust clinical validation, with over 200 peer-reviewed publications supporting the high accuracy of its tests.\u003c\/p\u003e\n\u003cp\u003eThe company consistently presents new data at major medical conferences, like the American Society of Clinical Oncology (ASCO) in 2024, further solidifying the clinical utility of products such as Signatera for MRD monitoring.\u003c\/p\u003e\n\u003cp\u003eThis commitment builds strong trust with clinicians and payers, driving broader adoption and reimbursement, reflected in their projected 2024 revenue growth.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cstrong\u003eOver 200 peer-reviewed publications validate Natera's test accuracy.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eConsistent data presentations at major conferences like ASCO 2024 enhance clinical utility.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eSignatera's strong evidence base supports its growing market adoption for MRD.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eClinical validation is key to driving payer reimbursement and revenue growth into 2025.\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdvanced Diagnostics Drive Market Leadership and Strong Growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eNatera’s advanced cfDNA technology, backed by 220 patents, drives its market-leading diagnostics like Panorama and Signatera. The company achieved $1.7 billion in 2024 revenue with 56.7% growth and positive Q4 2024 cash flow. Its robust portfolio and strong market presence, including over 50% US NIPT share in 2024, are reinforced by over 200 peer-reviewed clinical validations. This solidifies Natera's competitive edge and future growth.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eStrength Category\u003c\/th\u003e\n\u003cth\u003eKey Metric\u003c\/th\u003e\n\u003cth\u003e2024\/2025 Data\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTechnological Edge\u003c\/td\u003e\n\u003ctd\u003ePatents Issued\u003c\/td\u003e\n\u003ctd\u003e~220 US\/Foreign\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFinancial Performance\u003c\/td\u003e\n\u003ctd\u003eTotal Revenue\u003c\/td\u003e\n\u003ctd\u003e$1.7 Billion (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMarket Dominance\u003c\/td\u003e\n\u003ctd\u003eUS NIPT Market Share\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;50% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eDelivers a strategic overview of Natera’s internal and external business factors, highlighting its strengths in genetic testing, weaknesses in profitability, opportunities in expanding diagnostics, and threats from competition and regulatory changes.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eProvides a clear, actionable framework for identifying and addressing Natera's strategic challenges and opportunities.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eW\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eeaknesses\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHistory of Net Losses and Accumulated Deficit\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDespite robust revenue growth, Natera faces challenges from its history of significant net losses. The company reported a net loss of $190.4 million in 2024 and held an accumulated deficit of $2.6 billion as of early 2025. While these losses are narrowing, this financial instability could limit crucial investments in research and development and expansion initiatives. Securing additional financing is essential to mitigate these constraints. Achieving consistent profitability remains a core challenge for Natera.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDependence on Reimbursement from Third-Party Payers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNatera's financial health is critically tied to reimbursement from a limited group of third-party payers, including major commercial insurers and government programs like Medicare. Any shifts in coverage policies or reductions in reimbursement rates, such as potential adjustments impacting their Q1 2024 revenue, could significantly diminish the company's profitability. Navigating this intricate and often unpredictable reimbursement landscape remains a persistent operational challenge for Natera.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh Operating Expenses\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eNatera faces a significant weakness in its high operating expenses, driven by substantial research and development and selling, general, and administrative costs. For 2025, the company projects R\u0026amp;D expenses to be between $525 million and $550 million. Additionally, SG\u0026amp;A costs are anticipated to range from $950 million to $975 million in 2025. These large expenditures, while essential for growth, directly contribute to ongoing net losses and create considerable pressure on Natera's path to achieving profitability.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eReliance on a Limited Number of Core Products\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eNatera's revenue historically relies heavily on its women's health portfolio, particularly the Panorama NIPT, creating a concentration risk. While the oncology segment, anchored by products like Signatera, is experiencing rapid growth, it has not yet fully diversified the company's income streams. As of early 2025, women's health still contributes a significant portion of total revenue, with Panorama remaining a key driver. Natera's long-term financial stability hinges on its continued success in expanding and commercializing its newer oncology and organ health offerings to balance its revenue base.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cstrong\u003eIn fiscal year 2024, women's health products, including Panorama NIPT, accounted for over 70% of Natera's total revenue.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eDespite a 2024 revenue increase of over 40% in the oncology segment, its overall contribution remains secondary to women's health.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eThe company's 2025 financial projections indicate a continued emphasis on scaling Signatera and Prospera to mitigate this reliance.\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLitigation and Patent Disputes\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eNatera operates in a highly litigious industry, frequently involved in costly patent infringement disputes. These ongoing legal battles, such as the significant litigation with CareDx, can divert management's focus and resources. An unfavorable outcome, like the jury award in the CareDx case, could materially impact Natera's financial position and business operations, potentially affecting its market valuation.\n\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cstrong\u003eLegal expenses impacted Natera's Q4 2023 net loss, which was -$151.7 million, partly due to these disputes.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eThe company has faced multiple patent infringement claims, leading to substantial legal outlays anticipated through 2024.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003ePotential adverse judgments could necessitate significant financial outflows, impacting future profitability and R\u0026amp;D investment.\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFinancial Instability: High Costs \u0026amp; Revenue Risks Persist\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eNatera faces persistent financial instability, marked by a $190.4 million net loss in 2024 and high 2025 operating expenses projected over $1.4 billion for R\u0026amp;D and SG\u0026amp;A. Its revenue heavily relies on women's health, comprising over 70% of 2024 revenue, creating concentration risk. This, coupled with reimbursement dependencies and ongoing costly litigation, poses significant operational and financial challenges to achieving consistent profitability.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eWeakness\u003c\/th\u003e\n\u003cth\u003e2024\/2025 Data\u003c\/th\u003e\n\u003cth\u003eImpact\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Losses\u003c\/td\u003e\n\u003ctd\u003e-$190.4M (2024)\u003c\/td\u003e\n\u003ctd\u003eLimits investment capacity\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOperating Expenses\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;$1.4B (2025 Proj.)\u003c\/td\u003e\n\u003ctd\u003ePressures profitability\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue Concentration\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;70% Women's Health (2024)\u003c\/td\u003e\n\u003ctd\u003eCreates market dependency\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Version Awaits\u003c\/span\u003e\u003cbr\u003eNatera SWOT Analysis\u003c\/h2\u003e\n\u003cp\u003eThe file shown below is not a sample—it’s the real SWOT analysis you'll download post-purchase, in full detail. This preview provides a clear overview of Natera's Strengths, Weaknesses, Opportunities, and Threats. You'll gain access to the complete, in-depth analysis upon purchase, enabling you to leverage this strategic information effectively. Prepare to receive a comprehensive document that mirrors this preview.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":55480592695673,"sku":"natera-swot-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/natera-swot-analysis.png?v=1752755739","url":"https:\/\/growthsharematrix.com\/products\/natera-swot-analysis","provider":"Growth Share Matrix","version":"1.0","type":"link"}